Coeptis Therapeutics Hldgs Inc (COEP) Stock Price, Quote & News

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology

Sector: Healthcare

Phone: 724 934 6467

Website: coeptistx.com

Address:

105 Bradford Road, Suite 420, Wexford, United States

HubAllianceModern Mar. 21 at 6:35 PM

$COEP showed up earlier, just noting it.

0 · Reply

AllAmerican82ndAirborne Mar. 21 at 12:24 AM

$COEP Hammer candle? 🤔

1 · Reply

Herrm Mar. 20 at 8:55 PM

$COEP https://www.ainvest.com/news/coep-posts-loss-buys-shares-stock-crumbles-2603/

1 · Reply

Truthurts Mar. 20 at 8:25 PM

$COEP - Nasdaq delay info in link. Texas is also holding it up due to power grid. Once ticker change official, GEAR shares distributed to ZSQR holders. https://finance.yahoo.com/news/vanderbilt-report-coeptis-z-squared-120700269.html

1 · Reply

AllAmerican82ndAirborne Mar. 20 at 8:17 PM

$COEP who got shaken out today??? 😂 come on raise those hands 🙋‍♂️

1 · Reply

Stokroulette Mar. 20 at 7:54 PM

$COEP eh I’ve seen better days whatever , time is 🔜

1 · Reply

daviddoe123 Mar. 20 at 5:30 PM

$COEP @The1Albatross the delay true?

0 · Reply

DesseinH Mar. 20 at 4:57 PM

$COEP The merger is delayed into Q2, will probably be a few more months unfortunately. They are having issues with nasdaq approval apparently. Explains why it went down i guess.

3 · Reply

DesseinH Mar. 20 at 2:40 PM

$COEP Can't believe this is trading so cheap, they should hear from Nasdaq sometime this week, imagine if they hear after hours clearance for ZSQR, they will announce the news, and people will be caught offside. I'm buying everything i can at these levels.

1 · Reply

daviddoe123 Mar. 20 at 2:39 PM

$COEP cmon soon?

0 · Reply

Coeptis Receives Shareholder Approval Towards Z Squared Merger

Jan 6, 2026, 8:19 AM EST - 2 months ago

Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared

Sep 23, 2025, 8:00 AM EDT - 6 months ago

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

Jul 22, 2025, 8:36 AM EDT - 8 months ago

Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd

Jun 26, 2025, 8:34 AM EDT - 9 months ago

Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared

May 28, 2025, 8:28 AM EDT - 10 months ago

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Apr 25, 2025, 8:33 AM EDT - 11 months ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 17, 2025, 8:38 AM EDT - 1 year ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Mar 11, 2025, 8:34 AM EDT - 1 year ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 7, 2025, 8:37 AM EST - 1 year ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 1 year ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

Feb 20, 2025, 9:00 AM EST - 1 year ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 7:27 AM EST - 1 year ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 13, 2025, 8:39 AM EST - 1 year ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 6, 2025, 8:08 AM EST - 1 year ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Jan 30, 2025, 8:27 AM EST - 1 year ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 23, 2025, 8:09 AM EST - 1 year ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 22, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 7, 2025, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Dec 27, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Announces Reverse Stock Split

Dec 26, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 1 year ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 3, 2024, 8:15 AM EST - 1 year ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Nov 7, 2024, 8:07 AM EST - 1 year ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Oct 24, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 15, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Sep 19, 2024, 7:07 AM EDT - 1 year ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 5, 2024, 8:07 AM EDT - 1 year ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

May 30, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 8, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 8:47 AM EDT - 2 years ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Feb 26, 2024, 9:00 AM EST - 2 years ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 7, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Jan 4, 2024, 7:30 AM EST - 2 years ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Dec 4, 2023, 7:30 AM EST - 2 years ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 24, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 9, 2023, 9:15 AM EDT - 2 years ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 4, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

$Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection$

Sep 14, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 11, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Aug 30, 2023, 1:00 PM EDT - 2 years ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 17, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Jun 16, 2023, 4:00 PM EDT - 3 years ago

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

HubAllianceModern Mar. 21 at 6:35 PM

$COEP showed up earlier, just noting it.

0 · Reply

AllAmerican82ndAirborne Mar. 21 at 12:24 AM

$COEP Hammer candle? 🤔

1 · Reply

Herrm Mar. 20 at 8:55 PM

$COEP https://www.ainvest.com/news/coep-posts-loss-buys-shares-stock-crumbles-2603/

1 · Reply

Truthurts Mar. 20 at 8:25 PM

1 · Reply

AllAmerican82ndAirborne Mar. 20 at 8:17 PM

$COEP who got shaken out today??? 😂 come on raise those hands 🙋‍♂️

1 · Reply

Stokroulette Mar. 20 at 7:54 PM

$COEP eh I’ve seen better days whatever , time is 🔜

1 · Reply

daviddoe123 Mar. 20 at 5:30 PM

$COEP @The1Albatross the delay true?

0 · Reply

DesseinH Mar. 20 at 4:57 PM

$COEP The merger is delayed into Q2, will probably be a few more months unfortunately. They are having issues with nasdaq approval apparently. Explains why it went down i guess.

3 · Reply

DesseinH Mar. 20 at 2:40 PM

1 · Reply

daviddoe123 Mar. 20 at 2:39 PM

$COEP cmon soon?

0 · Reply

watchlisten Mar. 20 at 2:39 PM

$COEP

1 · Reply

YuenglingSwing Mar. 20 at 2:30 PM

$COEP showing 10.28 here. Wtf? Guessing this is shorts last ditch effort. Mid March is the estimated closing time. Give us a fucking update!

0 · Reply

The1Albatross Mar. 20 at 2:29 PM

$COEP

2 · Reply

kobramaximus Mar. 19 at 11:53 PM

$COEP @YuenglingSwing Even though it feels slow, the milestones over the last 60 days have been moving at lightning speed compared to the previous year: January 30: Shareholders voted to approve all eight proposals (The point of no return). February 9: Nasdaq compliance was officially regained (The "Safety Net"). March 9: The Vanderbilt Report confirmed closing is "Imminent" and upped the miner count to 9,800 ASIC units. Hang in there! STAY STRONG!

0 · Reply

WonkyGorilla Mar. 19 at 10:47 PM

$COEP I found the cheat codes..!! If you just change the buy/sell candles the opposite colors, green to red, red to green.. you'll feel a whole lot better.. Youre welcome. 👍🏻😂

3 · Reply

kobramaximus Mar. 19 at 9:26 PM

$COEP

0 · Reply